Article List

WPRIM Management System> DCMS> Chinese Journal of Cancer Biotherapy> 2018> 25> 11

Volume: 25 Issue: 11

1. Progression in immunotherapy with immune checkpoint inhibitors for advanced gastric cancer	Page:1089—1093
2. Molecular classification of gastric cancer and individualized immunotherapy	Page:1094—1098
3. Problems and countermeasures of digestive endoscopy on gastric cancer in the era of precision medicine	Page:1099—1103
4. Long noncoding RNA FOXD2-AS1 incuced gastric cancer cell MGC-803 to apatinib resistance by regulating miR-185-5p/CCND2 modulating axis	Page:1104—1112
5. Effects of nuclear factor 5 of activated T cells on proliferation and apoptosis of human gastric cancer MGC803 cells	Page:1119—1124
6. Short term efficacy and toxicity of apatinib and docetaxel combined with cisplatin chemotherapy for advanced gastric cancer	Page:1131—1134
7. Clinical effect of apatinib combined with chemotherapy for advanced gastric cancer as second-line and above treatment	Page:1135—1139
8. miR-29c modulates apatinib resistance in gastric cancer tissues and cell via targeting TNRC18	Page:1140—1147
9. IL-17 gene rs763780 polymorphism and susceptibility of gastric cancer：a Metaanalysis	Page:1148—1153
10. Research progress of exosomes in the occurrence and development of gastric cancer	Page:1154—1158
11. Comparative study on the inhibitory effect of dual specific oncolytic adenovirus and doxorubicin on breast cancer cells	Page:1159—1165
12. Role of LncRNA RP11-513G11.1 in chemoresistance and prognosis evaluation in patients with small cell lung cancer	Page:1166—2270
13. Expression of HOXA10 gene and its biological effects in endometrial carcinoma	Page:1171—1175
14. Clinical efficacy of bevacizumab combined with cisplatin regimen in the treatment of malignant pleural effusion in lung cancer patients	Page:1176—1179
15. Research progress on the role of CAFs in tumors	Page:1180—1184
16. Advances in gut microbiota and hepatocellularcarcinoma	Page:1185—1190
17. The role of LL-37 in tumor development	Page:1191—1199
18. Advances in the clinical management of HER2-positive breast cancer	Page:1200—1204